Top

Published in:

Open Access 01-04-2010 | Review

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants

Authors: Jan Buitelaar, Rossella Medori

Published in: European Child & Adolescent Psychiatry | Issue 4/2010

Abstract

Attention-deficit/hyperactivity disorder (ADHD), one of the most common neuropsychiatric conditions of childhood, often has a chronic course and persists into adulthood in many individuals. ADHD may have a clinically important impact on health-related quality of life in children, a significant impact on parents’ emotional health and interfere with family activities/cohesion. To date, the main targets of ADHD treatment have focused on reducing the severity of symptoms during the school day and improving academic performance. However, the treatment of ADHD should reach beyond symptom control to address the issues of social competencies and improvement of health-related quality of life from the perspectives of individuals with ADHD and their families, to support them in reaching their full developmental potential. Methylphenidate (MPH) is recognised as the first-line choice of pharmacotherapy for ADHD in children and adolescents. This paper focuses on the importance and benefits to child development of ADHD symptom control beyond the school day only, i.e. extending into late afternoon and evening and uses the example of an extended-release MPH formulation (OROS^® MPH) to demonstrate the potential benefits of active full day coverage (12 h) with a single daily dose. Concerns of long-term stimulant treatment are also discussed.

Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, Riddle M, Oatis M, Greenhill L, Skrobala A, March J, Gammon P, Robinson J, Lazell R, McMahon DJ, Ritz L (2005) Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 44:418–427PubMed

American Psychiatric Association (1994) Diagnsotic and statistical manual for mental disorders: fourth edition (DSM-IV). American Psychiatric Association, Washington, DC

Bagwell CL, Molina BS, Pelham WE Jr, Hoza B (2001) Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 40:1285–1292PubMed

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495PubMed

Barkley RA (2004) Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments. J Psychiatr Pract 10:39–56PubMed

Barkley RA (1998) Attention-deficit hyperactivity disorder. A handbook for diagnosis and treatment, 2nd edn. The Guildford Press, New York

Barkley RA (2002) Psychosocial treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 63(Suppl 12):36–43PubMed

Bener A, Qahtani RA, Abdelaal I (2006) The prevalence of ADHD among primary school children in an Arabian society. J Atten Disord 10:77–82PubMed

Biederman J (1998) Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 59:4–16PubMed

10.

Biederman J (2003) Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 64:3–8PubMed

11.

Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV (2008) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 165:597–603PubMed

12.

Biederman J, Newcorn J, Sprich S (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564–577PubMed

13.

Bloom B, Dey AN, Freeman G (2006) Summary health statistics for US children: national health interview survey, 2005. Vital Health Stat 231:1–84

14.

Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD (2009) Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 50:335–342PubMed

15.

Chan E, Zhan C, Homer CJ (2002) Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch Pediatr Adolesc Med 156:504–511PubMed

16.

Characteristics SSoP http://www.keele.ac.uk/schools/pharm/MTRAC/ProductInfo/verdicts/A/ATOMOXETINE.PDF

17.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H (2009) Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosci 63:167–175PubMed

18.

Chronis AM, Jones HA, Raggi VL (2006) Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. Clin Psychol Rev 26:486–502PubMed

19.

Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J (2008) Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health 2:31PubMed

20.

Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev B (2004) Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract 17:235–239PubMed

21.

Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B (2006) Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics 118:e704–e710PubMed

22.

Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS (2004) Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 43:269–275PubMed

23.

Diamond IR, Tannock R, Schachar RJ (1999) Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 38:402–409PubMed

24.

Donenberg G, Baker BL (1993) The impact of young children with externalizing behaviors on their families. J Abnorm Child Psychol 21:179–198PubMed

25.

Excellence NIfC (2006) Technology appraisal guidance No. 13. Guidance on the use of methyphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood. National Institute for Clinical Excellence, October 2003. http://www.nice.org.uk

26.

Faber A, van Agthoven M, Kalverdijk L (2006) Cost effectiveness of long-acting methylphenidate OROS (Concerta XL) in ADHD youths with suboptimal symptom control of immediate-release methylphenidate in The Netherlands. Poster presented at ISPOR 9th annual European congress, Copenhagen, Denmark, 28–31 Oct 2006

27.

Faraone SV, Biederman J, Morley CP, Spencer TJ (2008) Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994–1009PubMed

28.

Faraone SV, Sergeant J, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113PubMed

29.

Favreau A, Deseille-Turlotte G, Brault F, Giraudeau B, Krier C, Barthez MA, Castelnau P (2006) Benefit of the extended-release methylphenidate formulations: a comparative study in childhood. Arch Pediatr 13:442–448PubMed

30.

Fischer AG, Bau CH, Grevet EH, Salgado CA, Victor MM, Kalil KL, Sousa NO, Garcia CR, Belmonte-de-Abreu P (2007) The role of comorbid major depressive disorder in the clinical presentation of adult ADHD. J Psychiatr Res 41(12):991–996

31.

Garland EJ (1998) Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 12:385–395PubMed

32.

Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS (2006) Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol 16:286–297PubMed

33.

Greenhill LL, Halperin JM, Abikoff H (1999) Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503–512PubMed

34.

Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI (2003) Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 18:109–112PubMed

35.

Guevara J, Lozano P, Wickizer T, Mell L, Gephart H (2001) Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 108:71–78PubMed

36.

Hartup WW (1992) Having friends, making friends and keeping friends: relationships as educational contexts. Urban, IL: ERIC Clearing house on elementary and early childhood education. Eric Digest 345 854

37.

Hechtman L (2000) Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 9:481–498PubMed

38.

Hechtman L, Abikoff H, Klein RG, Weiss G, Respitz C, Kouri J, Blum C, Greenfield B, Etcovitch J, Fleiss K, Pollack S (2004) Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43:812–819PubMed

39.

Heger S, Trott GE, Meusers M, Schulz E, Rothenberger A, Rettig K, Medori R, Schreiner A, Remschmidt H (2006) Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD. Zeitschrift fur Kinder and Jugendpsychiatrie Psychotherapie 34:257–265

40.

Hemmer SA, Pasternak JF, Zecker SG, Trommer BL (2001) Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 24:99–102PubMed

41.

Hoare P, Beattie T (2003) Children with attention deficit hyperactivity disorder and attendance at hospital. Eur J Emerg Med 10:98–100PubMed

42.

Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, Schmit M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE (2005) 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 14:305–309PubMed

43.

James A, Lai FH, Dahl C (2004) Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 110:408–415PubMed

44.

Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B (2001) ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40:147–158PubMed

45.

Johnson C, Mash EJ (2001) Families with children with ADHD: review and recommendations for future research. Clin Child Fam Psychol Rev 3:183–207

46.

Kelly TM, Cornelius JR, Clark DB (2004) Psychiatric disorders and attempted suicide among adolescents with substance use disorders. Drug Alcohol Depend 73:87–97PubMed

47.

Kemner JE, Lage MJ (2006) Effect of methylphenidate formulation on treatment patterns and use of emergency room services. Am J Health Syst Pharm 63:317–322PubMed

48.

Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS (2005) Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 22:498–512PubMed

49.

Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN (2009) Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol 24:95–102PubMed

50.

Klassen AF, Miller A, Fine S (2004) Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 114:e541–e547PubMed

51.

Kollins SH (2003) Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry 64:14–18PubMed

52.

Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41:776–784PubMed

53.

Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11–28PubMed

54.

Lage M, Hwang P (2004) Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 14:575–581PubMed

55.

Landgraft JL, Abetz K, Ware JE (1996) The CHQ user’s manual. The Health Institute, New England Medical Center, Boston

56.

LeFever GB, Dawson KV, Morrow AL (1999) The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health 89:1359–1364PubMed

57.

Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O’Brien PC (2001) Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 285:60–66PubMed

58.

Lynch F, Mills C, Daly I, Fitzpatrick C (2006) Challenging times: prevalence of psychiatric disorders and suicidal behaviours in Irish adolescents. J Adolesc 29:555–573PubMed

59.

Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M (1993) Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565–576PubMed

60.

Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, Castellanos FX (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 165:604–609PubMed

61.

Marchetti A, Magar R, Lau H, Murphy EL, Jensen PS, Conners CK, Findling R, Wineburg E, Carotenuto I, Einarson TR, Iskedjian M (2001) Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 23:1904–1921PubMed

62.

McClure A, Prasad S, Poole L (2005) Functional outcomes of children with attention deficit hyperactivity disorder in the UK. Arch Dis Childhood 90:A48–A50

63.

Molina BS, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliott GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007) Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46:1028–1040PubMed

64.

Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48:484–500PubMed

65.

Moore JL, McAuley JW, Long L, Bornstein R (2002) An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients. Epilepsy Behav 3:92–95PubMed

66.

Murphy K (2005) Psychosocial treatments for ADHD in teens and adults: a practice-friendly review. J Clin Psychol 61:607–619PubMed

67.

Murphy K, Barkley RA (1996) Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 37:393–401PubMed

68.

Nada-Raja S, Langley JD, McGee R, Williams SM, Begg DJ, Reeder AI (1997) Inattentive and hyperactive behaviors and driving offenses in adolescence. J Am Acad Child Adolesc Psychiatry 36:515–522PubMed

69.

National Institute for Clinical Excellence (2000) Technology appraisal guidance No. 13. Guidance on the use of methyphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood. October

70.

National Institute for Clinical Excellence (2006) Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults 2006. http://www.nice.org.uk/guidance/index.jsp?action=download&o=34227

71.

National Institute for Clinical Excellence (2003) Technology appraisal guidance No. 13. Guidance on the use of methyphenidate (Ritalin, Equasym) for attention-deficit/hyperactivity disorder (ADHD) in childhood

72.

Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 165:721–730PubMed

73.

Nissen SE (2006) ADHD drugs and cardiovascular risk. N Engl J Med 354:1445–1448PubMed

74.

O’Driscoll GA, Depatie L, Holahan AL, Savion-Lemieux T, Barr RG, Jolicoeur C, Douglas VI (2005) Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1452–1460PubMed

75.

Owens JA, Maxim R, Nobile C, McGuinn M, Msall M (2000) Parental and self-report of sleep in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 154:549–555PubMed

76.

Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV (2004) Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 14:185–194PubMed

77.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105PubMed

78.

Perrin JM, Friedman RA, Knilans TK (2008) Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122:451–453PubMed

79.

Pliszka S, American Academy of Child and Adolescent Psychiatry (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921PubMed

80.

Pliszka SR (1989) Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 28:882–887PubMed

81.

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948PubMed

82.

Poulton A, Cowell CT (2003) Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39:180–185PubMed

83.

Rapport MD, Moffitt C (2002) Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 22:1107–1131PubMed

84.

Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R (2005) Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 14:297–304PubMed

85.

Robb A, Stein M (2002) Parent preference for OROS methylphenidate over methylphenidate tid. Poster presented at 155th annual meeting of the American Psychiatry Association, Philadelphia, 18–23 May 2002

86.

Scottish Intercollegiate Guidelines Network (2001) Attention deficit and hyperkinetic disorders in children and young people. A national clinical guidelines No. 52. SIGN, Edinburgh

87.

Sleator EK, Ulmann RK, von Neumann A (1982) How to hyperactive children feel about taking stimulatnts and will they tell their doctor? Clin Pediatr 21:474–479

88.

Sobanski E, Alm B (2005) Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder. Nervenarzt 76:1412–1417PubMed

89.

Sobanski E, Alm B, Krumm B (2007) Effect of subtype and psychiatric comorbidities on methylphenidate treatment in adults with attention-deficit hyperactivity disorder. Nervenarzt 78:328–337PubMed

90.

Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432PubMedCrossRef

91.

Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B (2006) Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 45:527–537PubMed

92.

Starfield B, Riley A, Ensminger M (2000) Manual for the child health and illness profile—child edition (CHIP-CE). The John Hopkins University, Baltimore, MD

93.

Starr HL, Kemner J (2005) Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Natl Med Assoc 97:11S–16SPubMed

94.

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE (2006) A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 13:e50–e62PubMed

95.

Stein MA (1999) Unravelling sleep problems in treated and untreated children with ADHD. J Child Adolesc Psychopharmacol 9:157–168PubMed

96.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH (2003) A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112:e404PubMed

97.

Swanson J (2003) Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 17:117–131PubMed

98.

Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S (1999) Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295–305PubMed

99.

Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulder E, Wigal S (2003) Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60:204–211PubMed

100.

Swanson J, Sadeh A, Lerner M (2001) Comparison of the impact of OROS methylphenidate HCL with methylphenidate tid and placebo on the sleep of children with ADHD. Reported in: Keating GM, McClellan K, Jarvis B. Methylphendiate (OROS formulation). CNS Drugs 15:495–503

101.

Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND (2007) Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46:1015–1027PubMed

102.

Tannock R, Ickowicz A, Schachar R (1995) Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 34:886–896PubMed

103.

Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):17–30

104.

The MTA Cooperative Group (1999) A 14-month randomised clinical trial of treatment of strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 56:1073–1086

105.

Torres AR, Whitney J, Gonzalez-Heydrich J (2008) Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 12:217–233PubMed

106.

Trautmann-Villalba P, Gerhold M, Polowczyk M, Dinter-Jorg M, Laucht M, Esser G, Schmidt MH (2001) Mother-child interaction and externalizing disorders in elementary schoolchildren. Zeitschrift fur Kinder und Jugendpsychiatri Psychotherapie 29(4):263–273

107.

van der Feltz-Cornelis CM, Aldenkamp AP (2006) Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. Epilepsy Behav 8:659–662PubMed

108.

van der Heijden KB, Smits MG, Gunning WB (2006) Sleep hygiene and actigraphically evaluated sleep characteristics in children with ADHD and chronic sleep onset insomnia. J Sleep Res 15:55–62PubMed

109.

Vance AL, Luk ES, Costin J, Tonge BJ, Pantelis C (1999) Attention deficit hyperactivity disorder: anxiety phenomena in children treated with psychostimulant medication for 6 months or more. Aust N Z J Psychiatry 33:399–406PubMed

110.

Vanoverbeke N, Annemans L, Ingham M, Price M, Adriaenssen I (2003) A cost-consequence analysis of the management of attention deficit hyperactivity disorder (ADHD) in the UK. Poster presented at ISPOR 8th annual meeting, Arlington, VA, 18–21 May 2003

111.

Volkow ND, Swanson JM (2008) Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 165:553–555PubMed

112.

Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR (2007) Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 41:222–230PubMed

113.

Wells KC, Chi TC, Hinshaw SP, Epstein JN, Pfiffner L, Nebel-Schwalm M, Owens EB, Arnold LE, Abikoff HB, Conners CK, Elliot GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March J, Newcorn JH, Pelham WE, Severe JB, Swanson J, Vitiello B, Wigal T (2006) Treatment-related changes in objectively measured parenting behaviours in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol 74:649–657PubMed

114.

Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M (2005) ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44:1015–1023PubMed

115.

Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424–433PubMed

116.

Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185PubMed

117.

Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 66:253–259PubMed

118.

Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM (2006) Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 160:82–90PubMed

119.

Wilens TE, Spencer TJ (2000) The stimulants revisited. Child Adolesc Psychiatr Clin N Am 9:573–603PubMed

120.

Wolraich ML, Doffing MA (2004) Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs 18:243–250PubMed

121.

Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883–892PubMed

Title: Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants
Authors: Jan Buitelaar
Rossella Medori
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: European Child & Adolescent Psychiatry / Issue 4/2010
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-009-0056-1

2024 ASCO Annual Meeting

Springer Medicine

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis

Maternal depressive symptoms, and not anxiety symptoms, are associated with positive mother–child reporting discrepancies of internalizing problems in children: a report on the TRAILS Study

Course of intelligence deficits in early onset, first episode schizophrenia: a controlled, 5-year longitudinal study

The role of acquaintanceship in the perception of child behaviour problems

Stability of childhood anxiety disorder diagnoses: a follow-up naturalistic study in psychiatric care

Prolonged stay at the paediatric intensive care unit associated with paediatric delirium